Introduction: Radionuclide therapy (RNT) has emerged as a promising modality for cancer treatment. A radioisotope (166Ho) containing mesoporous silica nanoparticles was previously developed in the lab for internal RNT with tumor-specific delivery[1]. While the direct cytotoxic effects of ionizing radiation are well-established, emerging evidence suggests radiation can elicit immunomodulatory responses, trigger abscopal effect and enhance immune cell infiltration. So, we aim to investigate the immunomodulatory properties of 166Ho-MSNs, stimulation of abscopal effects and the subsequent treatment outcome.
Learning Objectives:
Understand the development of a novel radionuclide therapy using nanoparticles as carriers.
Understand evaluation of immunomodulation induced in vivo and in vitro, using mice and 3D spheroids.
